Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

Completed · Not applicable

Conditions studied: Candidiasis, Oral, HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.

Key facts

Study ID

NCT00002394

Run by

Novartis

People needed

30

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are at least 18 years old.
• Have thrush that has not responded to at least 10 days of fluconazole treatment.
• Are HIV-positive.
• Are expected to live at least 4 weeks.
• Are able to take oral medication.

You may not qualify if…

• You will not be eligible for this study if you:
• Have liver or kidney disease.
• Have received certain medications.
• Have a history of serious diarrhea or digestive problems.
• Are pregnant or breast-feeding.

Where it is running

• Therafirst Med Ctr — Fort Lauderdale, Florida, United States
• Associates in Research — Fort Myers, Florida, United States
• Clireco Inc — Tamarac, Florida, United States
• Infectious Diseases Research Inc — Tampa, Florida, United States
• Northwestern Univ / Division of Infectious Disease — Chicago, Illinois, United States
• Saint Michaels Med Ctr / Infectious Disease Resch Dpt — Newark, New Jersey, United States
• St Vincents Hosp / Clinical Research Program — New York, New York, United States
• Univ of Texas Med Branch — Galveston, Texas, United States
• Hampton Roads Med Specialists — Hampton, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.